TY -的T1 - Nontuberculosis分枝杆菌感染ions: would there be pharmacodynamics without pharmacokinetics? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01806-2019 VL - 54 IS - 5 SP - 1901806 AU - Kwak, Nakwon AU - Dalcolmo, Margareth Pretti AU - Daley, Charles L. AU - Eather, Geoffrey AU - Hasegawa, Naoki AU - Koh, Won-Jung AU - Thomson, Rachel AU - van Ingen, Jakko AU - Yim, Jae-Joon Y1 - 2019/11/01 UR - //www.qdcxjkg.com/content/54/5/1901806.abstract N2 - We appreciate the comments from H.Y. Kim and co-workers on our individual patient data meta-analysis on Mycobacterium abscessus pulmonary disease (MAB-PD) [1]. They emphasised the importance of pharmacokinetic (PK)/pharmacodynamic (PD) analysis and therapeutic drug monitoring (TDM) in the field of nontuberculous mycobacterial (NTM) disease, especially for MAB-PD. We generally agree with their perspective.Pharmacokinetic, pharmacodynamic and therapeutic drug monitoring data are useful in optimising treatment for Mycobacteriuam abscessus pulmonary disease, but such data are not routinely collected and analysis for clinical practice is difficult http://bit.ly/2pcTIUn ER -